Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study

Background The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical se...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2022-09, Vol.29 (5), p.796-807
Hauptverfasser:	Kikawa, Yuichiro, Kotake, Takeshi, Tsuyuki, Shigeru, Kang, Yookija, Takahara, Sachiko, Fujimoto, Yuri, Yamashiro, Hiroyasu, Yoshibayashi, Hiroshi, Takada, Masahiro, Yasuoka, Rie, Nakatsukasa, Katsuhiko, Yamagami, Kazuhiko, Suwa, Hirofumi, Okuno, Toshitaka, Nakayama, Ichiro, Kato, Tatsushi, Ogura, Nobuko, Moriguchi, Yoshio, Ishiguro, Hiroshi, Kagimura, Tatsuo, Taguchi, Tetsuya, Sugie, Tomoharu, Toi, Masakazu
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Anthracyclines Breast cancer Cancer Cancer Research Chemotherapy Estrogen Information management Medical research Medicine Medicine & Public Health Medicine, Experimental Metastasis Oncology Original Article Surgery Surgical Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!